Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

Sino Biopharmaceutical granted AstraZeneca rights to develop a chronic respiratory disease drug outside China for total payments of up to $1.9B. The deal provides upside-linked milestone/consideration potential, generally supportive of company fundamentals. Impact is likely most meaningful for sector sentiment rather than immediate market-wide pricing.

Analysis

Sino Biopharmaceutical granted AstraZeneca rights to develop a chronic respiratory disease drug outside China for total payments of up to $1.9B. The deal provides upside-linked milestone/consideration potential, generally supportive of company fundamentals. Impact is likely most meaningful for sector sentiment rather than immediate market-wide pricing.